Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Apidel logo — Revolutionizing Therapeutics through Cutting-Edge Drug Deliv...

Apidel

Revolutionizing Therapeutics through Cutting-Edge Drug Delivery Solutions

Founded 2011 Series C Biotechnology, Pharmaceutical

General Information

Company Name Apidel
Founded Year 2011
Industries Biotechnology, Pharmaceutical
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Apidel. To contact Apidel, visit apidel.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Apidel compare?

A PDF of Apidel and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Apidel soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Apidel

Apidel, an early-stage Swiss pharmaceutical company established in 2011, is focused on revolutionizing therapeutics through cutting-edge drug delivery solutions. Founded by two University of Geneva researchers and an industry executive, Apidel specializes in proprietary drug delivery technologies that improve the efficacy, safety, and cost-effectiveness of therapeutic products, thereby enhancing patient adherence to treatments. Apidel's expertise lies in reformulating both new and established drugs to maximize their therapeutic potential, creating opportunities for new indications for existing drug molecules. With a growing portfolio of granted patents and patent applications, Apidel protects all drugs formulated using its proprietary technologies. The company collaborates with pharmaceutical partners and maintains an internal pipeline of products using approved pharmaceuticals, thereby reducing clinical and regulatory risks and expediting development. Notably, Apidel's Series C investment in February 2017 from Valley Road Capital demonstrates investor confidence in its innovative approach. Apidel's name, derived from API (Active Pharmaceutical Ingredient) Delivery, underscores its technical proficiency in pharmaceutical formulation and effective drug delivery using polymeric vehicles. With an extensive product pipeline and strategic partnerships, Apidel is poised to create significant value for shareholders and make a lasting impact in the biotechnology and pharmaceutical industries.

Business keywords: Pharmaceuticals, Drug delivery, Therapeutics, Polymeric vehicles, Medical technology, Research and development, Patent portfolio, Clinical development, Regulatory compliance, Partnerships, Geneva, Swiss company, Early-stage startup, Proprietary technologies, University research

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series C Undisclosed 1
valley road capital
02 Feb 2017

Apidel Alternatives & Competitors

View All Alternatives
Apidel vs
Lyra Therapeutics
Lyra Therapeutics

Innovative solutions for precise, localized treatments in ear, nose, and throat care.

Post-IPO Equity
51-200 employees
Biotechnology, Health Care
Apidel vs
Cristal Therapeutics
Cristal Therapeutics The Netherlands

CliCr as next generation metal-free click chemistry for faster, cheaper and better bioconjugate prod...

Grant
4 employees
Biotechnology, Health and Wellness
Apidel vs
BioVersys AG
BioVersys AG Switzerland

Leadership in overcoming the antibiotic resistance crisis.

Series C
27 employees
Biotechnology, Pharmaceutical
Compare Apidel vs BioVersys AG
Also compare with: Apidel vs Souvie Biodelivery Souvie Biodelivery View all alternatives

FAQ About Apidel

Revolutionizing Therapeutics through Cutting-Edge Drug Delivery Solutions
Apidel was founded in 2011.
Apidel operates in Biotechnology and Pharmaceutical. Its work centres on Pharmaceuticals, Drug delivery, Therapeutics and Polymeric vehicles.
Apidel has completed 1 funding round. The latest funding stage is Series C.
Top alternatives and competitors to Apidel include Lyra Therapeutics, Cristal Therapeutics, BioVersys AG, IXALTIS SA, Orexo AB publ. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Apidel and Lyra Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Apidel, https://bouncewatch.com/company/apidel, updated 2 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes